journal
MENU ▼
Read by QxMD icon Read
search

P & T: a Peer-reviewed Journal for Formulary Management

journal
https://www.readbyqxmd.com/read/28479845/research-briefs
#1
(no author information available yet)
No abstract text is available yet for this article.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479844/american-college-of-cardiology
#2
Walter Alexander
We report on selected research presented at the ACC 66th Annual Scientific Session and Expo, including sessions on proprotein convertase subtilisin/kexin type 9 inhibitors, anti-Xa anticoagulants, and a direct thrombin inhibitor.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479843/usp-800-adds-significant-safety-standards-facility-upgrades-needed-to-protect-employees-from-hazardous-drugs
#3
Bruce E Beans
The new USP standard for handling hazardous drugs (HDs) will require millions of dollars in capital outlays for facility and equipment upgrades and also requires in-depth assessments of each HD that facilities handle, significant workflow and work practice changes, and thorough staff training.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479842/pbm-p-t-practices-the-heat-initiative-is-gaining-momentum
#4
Martha M Rumore, F Randy Vogenberg
The pharmacy benefit management (PBM) industry has recently fallen into the crosshairs of government investigations about the high cost of pharmaceuticals. The authors focus on the PBM-based P&T and formulary practices under scrutiny.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479841/hepatitis-c-in-a-new-era-a-review-of-current-therapies
#5
Troy Kish, Andrew Aziz, Monica Sorio
The authors summarize newly available HCV treatment regimens, their indications, studies supporting their efficacy and safety, and special considerations for each regimen, such as patient comorbidities.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479840/new-user-fee-agreements-aim-at-ensuring-relief-from-high-drug-prices-but-trump-s-budget-proposal-threatens-to-upend-completed-negotiations
#6
Stephen Barlas
The next iterations of the Generic Drug User Fee Act and the Biosimilar User Fee Act are meant to encourage new generic and biosimilar products, but higher fees and budget reductions may threaten progress.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479839/otiprio-an-fda-approved-ciprofloxacin-suspension-gel-for-pediatric-otitis-media-with-effusion
#7
Ann L Edmunds
Otiprio: an FDA-approved ciprofloxacin suspension gel for pediatric otitis media.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479838/debating-the-role-of-the-heart
#8
COMMENT
George Brengelmann
No abstract text is available yet for this article.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479837/pharmaceutical-approval-update
#9
Mary Choy
Brodalumab (Siliq) for moderate-to-severe plaque psoriasis in adults; telotristat ethyl (Xermelo) for carcinoid syndrome diarrhea in combination with somatostatin analogue therapy in adults; and desmopressin acetate (Noctiva) for adults with nocturnal polyuria.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479836/drug-and-device-news
#10
(no author information available yet)
Approvals, new indications, regulatory activities, and more.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479835/drug-companies-worry-about-new-totality-of-evidence-standard-is-it-an-about-face-from-the-fda-on-off-label-promotion
#11
Stephen Barlas
Drug companies worry about new FDA "totality of evidence" standard.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28479834/be-wary-of-misspeakers-who-shoot-from-the-hip
#12
Matthew Grissinger
Speaking "off the cuff" is a prescription for disaster in health care.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28381922/research-briefs
#13
(no author information available yet)
No abstract text is available yet for this article.
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28381921/clinical-interventional-oncology-symposium-and-integrative-healthcare-symposium
#14
Walter Alexander
We focus on liver-directed cancer therapy and the role of yittrium-90, as well as one clinician's controversial position against routine use of opioids for chronic pain.
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28381920/promising-drugs-in-clinical-development-to-treat-advanced-colorectal-cancer
#15
Chris Fellner
We present immunotherapies, biosimilars, and molecular-targeted agents in late-stage development for patients with advanced colorectal cancer.
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28381919/can-a-short-video-improve-apixaban-knowledge-in-an-inpatient-setting
#16
Christopher Giuliano, Thomas Nofar, Stephanie B Edwin
PURPOSE: To increase patient knowledge about apixaban (Eliquis, Bristol-Myers Squibb) using an educational video delivered in an urban inpatient setting. METHODS: This prospective, quasi-experimental study evaluated knowledge gain and retention in patients receiving apixaban after viewing a short educational video. Knowledge was assessed with a questionnaire immediately before, immediately after, and one month following the educational video. RESULTS: After 33 patients watched the video, scores increased by 19...
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28381918/evaluation-of-hydrocortisone-continuous-infusion-versus-intermittent-boluses-in-resolution-of-septic-shock
#17
Hoan Hoang, Shan Wang, Shahidul Islam, Adel Hanna, Alexander Axelrad, Collin Brathwaite
PURPOSE: To compare the effectiveness of continuous infusion of hydrocortisone versus intermittent boluses in the resolution of septic shock. METHODS: A retrospective chart review was performed to investigate the effects of low-dose hydrocortisone continuous infusion (200 mg per day) versus intermittent boluses (50 mg every six hours) in septic shock patients who did not respond to fluid resuscitation and vasopressors. The primary outcome was time to resolution of shock, defined by time from the initiation of hydrocortisone to time of vasopressor withdrawal when mean arterial pressure was greater than 65 mm Hg...
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28381917/dosing-of-enoxaparin-in-renal-impairment
#18
Suhail A Shaikh, Randolph E Regal
OBJECTIVE: To review enoxaparin treatment dosing, pharmacokinetics, and clinical outcomes data in patients with renal impairment and to examine the current two-tiered dosing regimen approved by the Food and Drug Administration (FDA). DATA SOURCES: A literature search of PubMed (1990-2016) was performed using the search terms low-molecular-weight heparin, unfractionated heparin, bleeding, enoxaparin, renal impairment, pharmacokinetics, and hemodialysis. STUDY SELECTION AND DATA EXTRACTION: All studies assessing the pharmacokinetic properties of enoxaparin in patients with renal impairment were evaluated...
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28381916/republicans-resolve-to-address-high-drug-prices-rhetoric-meets-reality-with-ppaca-replacement
#19
Stephen Barlas
As legislation is drafted to replace Obamacare, pharmaceutical issues-including controlling drug prices, expanding or contracting drug access, and incentivizing the development of generic drugs-are expected to be at the forefront of debate.
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28381915/flibanserin-addyi-the-first-fda-approved-treatment-for-female-sexual-interest-arousal-disorder-in-premenopausal-women
#20
Clayton English, Anne Muhleisen, Jose A Rey
Flibanserin (Addyi) for female sexual interest/arousal disorder in premenopausal women.
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
journal
journal
30579
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"